HSBC cuts AstraZeneca to hold as trial setback clouds valuation outlook
AstraZeneca faces fresh pressure after a late-stage heart disease trial misses its target and triggers a sharp share selloff. The setback prompts HSBC to abandon its bullish stance on the drugmaker and warn that confidence in its research pipeline is becoming more fragile.
Highlights
- HSBC downgrades AstraZeneca to hold from buy and cuts target price to £137.50 from £165, citing diminished risk-reward outlook.
- AstraZeneca shares drop as much as 9% Friday and are down 12% since its late-stage heart drug trial failed to meet targets.
- HSBC warns that further failed trials could trigger a valuation rerating, as premium stock pricing relies on confidence in R&D execution.
Broker downgrade follows trial miss
As reported by CNBC, HSBC says in a Monday research note that it downgrades AstraZeneca to hold from buy because it no longer sees the stock’s risk-reward balance as attractive.The bank also cuts its target price to £137.50 from £165, a reduction of more than 16%. HSBC says the British-Swedish drugmaker faces a tough path ahead after last week’s rare clinical trial failure, which sends AstraZeneca shares tumbling.
Shares of AstraZeneca fall as much as 9% on Friday after a late-stage clinical trial for a heart disease drug fails to meet its target. The stock is down 12% since the results are released.
Valuation pressure builds across pharma outlook
HSBC analysts say AstraZeneca’s premium valuation has long depended on market confidence in the company’s research and development engine. They warn that if bearish scenarios across upcoming trials materialize, three sequential losses could further weaken investor trust and open the way for a rerating.For years, AstraZeneca has traded at some of the highest valuations among major European pharmaceutical groups on expectations that management would continue delivering successful late-stage trials in oncology, rare diseases and specialty medicines. Under Chief Executive Pascal Soriot’s 14-year tenure, the company builds a reputation as a pharma powerhouse that rarely posts negative trial results.
In our earlier article on AstraZeneca’s $600 million upfront deal with Dizal Pharmaceutical for global rights to a targeted lung cancer therapy, we noted that the acquisition expands the company’s oncology pipeline but tightens near-term cash. We also highlighted that AZN shares were already showing persistent bearish technical momentum, trading below key moving averages, with downside risks dominating the short-term outlook.
Latest HSBC News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
